Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease
XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO®
First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented
THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news
More News: Cancer & Oncology | Immunotherapy | Myeloma | Pharmaceuticals | Reclast | Study | Toxicology | Xgeva | Zometa